◎ Sugi Atlas

Atlas / Disease / Central serous chorioretinopathy

Central serous chorioretinopathy

disease
On this page

Also known as central serous chorioretinopathy after bone marrow transplantationcentral serous choroidopathycentral serous retinopathyCSCCSCR

Summary

Central serous chorioretinopathy (MONDO:0018616) is a disease and 74 clinical trials. Top therapeutic interventions include eplerenone, verteporfin, and aflibercept. A subtype of retinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 74

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecentral serous chorioretinopathy
Mondo IDMONDO:0018616
MeSHD056833
Orphanet443079
ICD-10-CMH35.71
ICD-111623925689
NCITC115124
SNOMED CT312956001
UMLSC0730328
MedGen147591
GARD0000200
Is cancer (heuristic)no

Also known as: central serous chorioretinopathy after bone marrow transplantation · central serous choroidopathy · central serous retinopathy · CSC · CSCR

Disease family

This is a subtype of retinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › central serous chorioretinopathy

Related subtypes (31): retinal ischemia, rubeosis iridis, retinal vascular disorder, retinitis, retinal nerve fiber layer disorder, retinal edema, retinal degeneration, night blindness, hypertensive retinopathy, macular holes, retinal detachment, iris hypoplasia with glaucoma, angioid streaks, bradyopsia, myopic macular degeneration, osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome, congenital retinal arteriovenous communication, Eales disease, achromatopsia, cancer-associated retinopathy, persistent placoid maculopathy, inherited vitreoretinopathy, retina neoplasm, retinal ciliopathy, melanoma associated retinopathy, isolated foveal hypoplasia, acute macular neuroretinopathy, autoimmune retinopathy, proliferative vitreoretinopathy, isolated chorioretinal dystrophy, torpedo maculopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aflibercept, Bevacizumab, Brinzolamide, Eplerenone, Maltodextrin, Methotrexate, Mifepristone.

Clinical trials & evidence

Clinical trials

Clinical trials: 74.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified45
PHASE213
PHASE45
PHASE2/PHASE35
PHASE1/PHASE23
PHASE12
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01574430PHASE4COMPLETEDStudy of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)
NCT01797861PHASE4COMPLETEDProspective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy
NCT02462499PHASE4COMPLETEDEplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
NCT02681783PHASE4UNKNOWNPRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
NCT03079141PHASE4UNKNOWNPhotodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy
NCT06809751PHASE2/PHASE3NOT_YET_RECRUITINGEvaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
NCT00418431PHASE2/PHASE3WITHDRAWNIntravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
NCT02215330PHASE2/PHASE3UNKNOWNA Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
NCT02735213PHASE2/PHASE3COMPLETEDMicropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy
NCT05337332PHASE2/PHASE3UNKNOWNResults of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
NCT05633576PHASE3UNKNOWNSteroid Eye Drops in Chronic Central Serous Chorioretinopathy
NCT00211393PHASE2COMPLETEDA Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
NCT00211445PHASE2COMPLETEDPhotodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
NCT00489840PHASE1/PHASE2COMPLETEDTreatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
NCT00817245PHASE1/PHASE2COMPLETEDEffect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)
NCT00963131PHASE2COMPLETEDHigh-dose Antioxidants for Central Serous Chorioretinopathy
NCT00987077PHASE2COMPLETEDSelective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy
NCT01325181PHASE1/PHASE2COMPLETEDRanibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
NCT01633983PHASE2UNKNOWNMethotrexate for Central Serous Chorioretinopathy Treatment Trial
NCT01710332PHASE2COMPLETEDThe Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
NCT01822561PHASE2COMPLETEDEplerenone for Central Serous Chorioretinopathy
NCT01971190PHASE2COMPLETEDEfficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
NCT01975103PHASE2UNKNOWNNon-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
NCT02153125PHASE2UNKNOWNEplerenone For the Treatment of Chronic Central Serous Chorioretinopathy
NCT02354170PHASE2COMPLETEDShort-Term Oral Mifepristone for Central Serous Chorioretinopathy
NCT03542006PHASE2UNKNOWNBrinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy
NCT04356716PHASE2COMPLETEDSildenafil for Treatment of Choroidal Ischemia
NCT00403325PHASE1COMPLETEDIntravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
NCT02036632PHASE1COMPLETEDEye Patch Therapy for Central Serous Retinopathy (CSR)
NCT02141308Not specifiedRECRUITINGOCT in Rare Chorioretinal Diseases
NCT05570591Not specifiedRECRUITINGSubthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
NCT05589974Not specifiedRECRUITINGChoroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
NCT06346405Not specifiedRECRUITINGCentral Serous Chorioretinopathy and Micropulse Laser Treatment
NCT06468540Not specifiedNOT_YET_RECRUITINGCombination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
NCT06527326Not specifiedRECRUITINGthe Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
NCT07298174Not specifiedNOT_YET_RECRUITINGWide Field OCTA in Ocular Diseases
NCT07347119Not specifiedNOT_YET_RECRUITINGProspective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
NCT00403884Not specifiedUNKNOWNSelective RPE Laser Treatment (SRT) for Various Macular Diseases
NCT00802906Not specifiedCOMPLETEDBevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
NCT00803517Not specifiedCOMPLETEDComparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
EPLERENONE47
VERTEPORFIN43
AFLIBERCEPT41
BRINZOLAMIDE41
KETOCONAZOLE41
LEVOKETOCONAZOLE41
MIFEPRISTONE41
TRIAMCINOLONE ACETONIDE41
ANECORTAVE ACETATE31
MALTODEXTRIN31
CHEMBL613406903
CHEMBL32886301
CHEMBL7501
CHEMBL478194201

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvarefogardgenccgwasgwas_studyhgncicd10cmicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctidumls